Pharvaris (NASDAQ:PHVS) Price Target Raised to $30.00

Pharvaris (NASDAQ:PHVS) had its price objective upped by Wedbush from $27.00 to $30.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Pharvaris’ FY2029 earnings at $5.32 EPS.

PHVS has been the topic of a number of other reports. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $16.00 to $27.00 in a research note on Thursday, October 9th. JMP Securities dropped their price target on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Thursday. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.57.

Pharvaris Stock Performance

PHVS stock opened at $23.55 on Thursday. The firm has a 50 day moving average price of $23.20 and a 200-day moving average price of $20.68. Pharvaris has a 52-week low of $11.51 and a 52-week high of $26.33. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -7.34 and a beta of -2.78.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.08. As a group, sell-side analysts forecast that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

A number of large investors have recently made changes to their positions in the stock. TD Asset Management Inc lifted its position in Pharvaris by 41.5% during the first quarter. TD Asset Management Inc now owns 78,122 shares of the company’s stock valued at $1,227,000 after purchasing an additional 22,906 shares during the period. Deutsche Bank AG raised its stake in Pharvaris by 55.1% during the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after buying an additional 10,006 shares during the last quarter. Palumbo Wealth Management LLC lifted its holdings in shares of Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after buying an additional 447 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris in the 2nd quarter worth $57,000. Finally, Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.